Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease
Bradley J RobottomDepartment of Neurology, University of Maryland School of Medicine, Baltimore, MD, USAAbstract: Parkinson's disease (PD) is the second most common neurodegenerative disease and the most treatable. Treatment of PD is symptomatic and generally focuses on the replacement o...
Main Author: | Bradley J Robottom |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2011-01-01
|
Series: | Patient Preference and Adherence |
Online Access: | http://www.dovepress.com/efficacy-safety-and-patient-preference-of-monoamine-oxidase-b-inhibito-a6098 |
Similar Items
-
Cost-effectiveness of dopamine agonists and monoamine oxidase B inhibitors in Parkinson’s
by: McIntosh, E, et al.
Published: (2021) -
Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies
by: Makoto Naoi, et al.
Published: (2022-09-01) -
Controversies in Neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease
by: Reichmann Heinz, et al.
Published: (2011-09-01) -
Halogenated Coumarin–Chalcones as Multifunctional Monoamine Oxidase‑B and Butyrylcholinesterase Inhibitors
by: Nisha Abdul Rehuman, et al.
Published: (2021-10-01) -
Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system
by: Hiroto Asano, et al.
Published: (2023-11-01)